+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biospecimen Contract Research Services Market by Therapeutic Area, Type of Biospecimen, Type of Biospecimen for Non-Oncological Studies, Key Geographical Regions, Europe and Asia Pacific: Industry Trends and Global Forecasts, 2021-2030

  • ID: 5450265
  • Report
  • August 2021
  • Region: Asia Pacific, Europe, Global
  • 128 Pages
  • Roots Analysis

FEATURED COMPANIES

  • Accio Biobank Online
  • Biomedica CRO
  • Custom Science
  • HistoGeneX
  • NeuCyte
  • SampleSmart

Overview

Biomedical research is an evolutionary process involving a wide array of research experiments focused on studying diseases and their treatment options; biospecimens are credited as critical components of this process, starting from drug development to clinical trials and epidemiological investigations. Further, in the field of precision medicine, biospecimens act as a link between the biology of a patient and the development of customized therapy. However, procurement and storage of a high quality biospecimen and its analytical evaluation has remained a challenge in the pharmaceutical industry, resulting in delays in research and drug approval timeline. Reliable and efficient traceability of biospecimens demands unique identifiers, advanced data management and quality control systems. Moreover, there are legal and ethical concerns associated with biobanking, and laws and regulations regarding the upkeep of human biospecimens are still evolving.


Over the last few decades, the field of biospecimen research has witnessed significant technological advancements resulting in the procurement of high quality biospecimens for molecular research purposes. In fact, new best practices and improved methods of procurement, processing and storage of biospecimens have also been introduced to the industry. The pharmaceutical industry has seen a significant shift towards outsourcing the bioanalytical services to leverage cost-effective methods and overcome the existing capacity constraints. This shift is evident from the increase in partnership activity focused on expanding the existing capabilities of service providers and offering biospecimen procurement and analytical services. Based on the prevalent trends, we believe that more developers and innovators are likely to rely on the contract research organizations in order to deal with the existing challenges and drive innovation in drug development, thereby, increasing the opportunities for these service providers in the foreseen future.


Scope of the Report

The “Biospecimen Contract Research Services Market by Therapeutic Area (Oncological Disorders and Other Disorders), Type of Biospecimen for Oncological Studies (FFPE Tissue, Frozen Tissue, Plasma/Serum and Other Biospecimens), Type of Biospecimen for Non-Oncological Studies (Blood Products, Human Tissue and Other Biospecimens), Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World)): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study on the companies offering research services related to biospecimens. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. 


Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the companies that claim to offer research services related to biospecimens, including analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of blood products offered (plasma, serum, whole blood, blood cells and bone marrow), types of human tissues offered (Formalin-Fixed Paraffin-Embedded, frozen tissue and fresh tissue), types of biofluids offered (urine, saliva, cerebrospinal fluid, swab, synovial fluid, others), types of other biospecimens offered (fecal matter and nucleic acid), types of analytical services offered (histological analysis, target validation, tissue microarray, tumor tissue analysis and cell based assay), types of samples offered (healthy and diseased samples), types of accreditations received, and geographical reach (North America, Europe, Asia-Pacific and Rest of the World).
  • A detailed competitiveness analysis of the biospecimen contract research service providers based in different geographies offering services from their own biorepository or through the network of biorepositories, based on portfolio strength (in terms of number of biospecimens, number of analytical services and number of samples offered), service strength (in terms of number of accreditations and geographical reach), supplier strength (in terms of years of experience in this field and company size).
  • Tabulated profiles of key players offering a wide range of research services for the biospecimens across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, details on its biospecimen related services offered, types of blood products offered, types of human tissues offered, types of other biospecimens offered, types of analytical services offered, types of samples offered, geographic availability of the services, recent developments and an informed future outlook.
  • An analysis of partnerships established in this domain since 2015, covering the deals focused on the services related to biospecimens, merger/acqusition, service agreement, service alliance, distribution agreement, joint venture and other agreements.
  • A case study of the overall landscape of biospecimen procurement service providers (commercial biobanks), based on a number of parameters, such as year of establishment, company size, location of headquarters, types of services offered (sample collection, sample processing, sample logistic/transportation and sample storage), types of biospecimens handled (biofluids, human cells and tissues), therapeutic area (cardiovascular disorders, oncological disorders, neurological disorders, infectious diseases and other therapeutic areas). In addition, it presents a competitiveness analysis of the commercial biobanks based on the availability of their respective biorepositories.
  • An in-depth analysis of biospecimen contract research service providers, featuring four schematic representations, namely [A] a grid analysis based on the year of establishment and type of analytical services offered, [B] a representation based on the therapeutic area and most active players, [C] an analysis based on the company size and therapeutic area, and [D] a world map representation highlighting the regional distribution of biospecimen research service providers, based on the locations of their biorepositories. 

One of the key objectives of the report was to estimate the current market size and the growth opportunities in the biospecimen contract research services market, over the next decade. Based on different parameters, such as overall human biological sample market, share of commercial biobanks and share of biospecimen contract research service providers, we have provided informed estimates on the evolution of the market for the period 2021-2030. In order to provide a detailed future outlook, year-wise projections of the current and forecasted opportunity have been further segmented across [A] Therapeutic Area (Oncological Disorders and Other Disorders), [B] Type of Biospecimen for Oncological Studies (FFPE, Frozen Tissue, Plasma/Serum and Other Biospecimens), [C] Type of Biospecimen for Non-Oncological Studies (Blood Product, Human Tissue and Other Biospecimens), [D] Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World). In order to account for the uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.


The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The information presented in this study was also influenced by discussions held with senior stakeholders in this industry. The report features detailed transcripts of interviews held with the following individuals:


  • Ramchandra Rao (Managing Director and Business Development Head, BioSpecimen Solutions)
  • Oleg Granstrem (Director of Business Development, National BioService)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Key Questions Answered

  • Which are the leading contract researchers offering services related to biospecimens?
  • Which are the most common types of blood products offered by the biospecimen contract research service providers?
  • Where are the biorepositories owned by biospecimen contract research service providers located?
  • Which are the most common type of services offered by the biospecimen contract research service providers?
  • What type of services is offered by the commercial biobanks?
  • Which players are offering biospecimen related services through collaborations?
  • How is the current and future market opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Accio Biobank Online
  • Biomedica CRO
  • Custom Science
  • HistoGeneX
  • NeuCyte
  • SampleSmart

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biospecimen
3.3. Importance of Biospecimen in Drug Discovery and Research
3.4. Factors Affecting the Quality of Biospecimen
3.5. Biospecimen Management
3.6. Regulatory Guidelines
3.7. Outsourcing in Biospecimen Research
3.7.1. Role of Contract Research Organizations in Biospecimen Procurement
3.7.2. Types of Services Offered by Contract Research Organizations
3.8. Future Perspective


4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biospecimen Research Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Blood Product(s) Offered
4.2.5. Analysis by Type of Human Tissue(s) Offered
4.2.6. Analysis by Type of Biofluid(s) and Other Biospecimen(s) Offered
4.2.7. Analysis of Type of Analytical Service(s) Offered
4.2.8. Analysis by Type of Sample(s) Offered
4.2.9. Analysis of Accreditation(s) Received
4.2.10. Analysis by Geographical Reach


5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Key Parameters
5.4. Competitiveness Analysis: Biospecimen Research Service Providers with Biorepositories
5.4.1. Companies Offering Biospecimen Research Services in North America
5.4.2. Companies Offering Biospecimen Research Services in Europe and Asia-Pacific
5.5. Competitiveness Analysis: Biospecimen Research Service Providers without Biorepositories
5.5.1. Companies Offering Biospecimen Research Services in North America
5.5.2. Companies Offering Biospecimen Research Services in Europe


6. BIOSPECIMEN SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. BioChain Institute
6.2.1. Company Overview
6.2.2. Biospecimen Related Service Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. BioIVT
6.3.1. Company Overview
6.3.2. Biospecimen Related Service Portfolio 
6.3.3. Recent Developments and Future Outlook
6.4. Creative Bioarray
6.4.1. Company Overview
6.4.2. Biospecimen Related Service Portfolio 
6.4.3. Recent Developments and Future Outlook
6.5. Discovery Life Sciences 
6.5.1. Company Overview
6.5.2. Biospecimen Related Service Portfolio 
6.5.3. Recent Developments and Future Outlook
6.6. Infinity BiologiX
6.6.1. Company Overview
6.6.2. Biospecimen Related Service Portfolio 
6.6.3. Recent Developments and Future Outlook
6.7. Precision for Medicine
6.7.1. Company Overview
6.7.2. Biospecimen Related Service Portfolio 
6.7.3. Recent Developments and Future Outlook
6.8. PrecisionMed
6.8.1. Company Overview
6.8.2. Biospecimen Related Service Portfolio 
6.8.3. Recent Developments and Future Outlook


7. BIOSPECIMEN SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. Medicover
7.2.1. Company Overview
7.2.2. Biospecimen Related Service Portfolio 
7.2.3. Recent Developments and Future Outlook
7.3. National BioService
7.3.1. Company Overview
7.3.2. Biospecimen Related Service Portfolio 
7.3.3. Recent Developments and Future Outlook
7.4. REPROCELL
7.4.1. Company Overview
7.4.2. Biospecimen Related Service Portfolio 
7.4.3. Recent Developments and Future Outlook


8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Biospecimen Research Services: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Collaborator
8.3.4. Analysis by Type of Service(s) Offered
8.3.5. Analysis by Type of Biospecimen(s) Handled
8.3.6. Analysis by Therapeutic Area
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.4. Geographical Analysis
8.4.1. Intercontinental and intracontinental Agreements


9. CASE STUDY: MARKET LANDSCAPE OF COMMERCIAL BIOBANKS
9.1. Chapter Overview
9.2. Commercial Biobanks: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Analysis by Types of Service(s) Offered
9.2.5. Analysis by Types of Biospecimen(s) Handled
9.2.6. Analysis by Therapeutic Area
9.3. Company Competitiveness Analysis
9.3.1. Methodology and Key Parameters
9.3.2. Competitiveness Analysis: Commercial Biobanks with Biorepositories
9.3.3. Competitiveness Analysis: Commercial Biobanks without Biorepositories


10. KEY INSIGHTS
10.1. Chapter Overview
10.2 Grid Analysis: Analysis by Year of Establishment and Type of Analytical Service(s) Offered
10.3. Analysis by Company Size and Therapeutic Area
10.4 Most Active Players: Analysis by Therapeutic Area and
10.5. World Map Representation: Analysis by Location of In-House Biorepositories


11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall Biospecimen Research Services Market, 2021-2030
11.3.1. Biospecimen Research Services Market, 2021-2030: Distribution by Type of Biospecimen
11.3.2. Biospecimen Research Services Market, 2021-2030: Distribution by Therapeutic Area
11.3.3. Biospecimen Research Services Market, 2021-2030: Distribution by Key Geographical Regions
11.3.3.1. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Countries
11.3.3.2. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Type of Biospecimen
11.3.3.3. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Therapeutic Area
11.3.3.4. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Countries
11.3.3.5. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Type of Biospecimen
11.3.3.6. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Therapeutic Area
11.3.3.4. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Countries
11.3.3.5. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biospecimen
11.3.3.6. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area


12. CONCLUSION
12.1. Chapter Overview


13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. BioSpecimen Solutions
13.2.1. Overview of Company / Organization 
13.2.2. Interview Transcript: Ramachandra Rao, Managing Director and Business Development Head
13.3. National BioService
13.3.1. Overview of Company / Organization
13.3.2. Interview Transcript: Oleg Granstrem, Director of Business Development


14. APPENDIX 1: TABULATED DATA


15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS


Note: Product cover images may vary from those shown
  • Accio Biobank Online
  • Akoya Biosciences
  • Allcyte
  • AMSBIO
  • Analytical Biological Services
  • ApoCell
  • Applied Immunology
  • Ardent-Clinical Research Services
  • Ascendance Biotechnology (acquired by BioIVT)
  • Asterand Bioscience (acquired by BioIVT)
  • ATCG 
  • Atreide Biosamples
  • Audubon Bioscience
  • Aurora Health Care
  • Bay Biosciences
  • BIO|OPTIONS
  • BioChain Institute
  • Biognosys
  • BioIVT (formerly BioreclamationIVT)
  • BioKaizen
  • Biological Industries
  • Biological Specialty Company (acquired by BioreclamationIVT)
  • Biomedica CRO
  • Bioneer
  • BioPartners
  • Biopta (a part of ReproCell)
  • Biospecimen Solutions
  • Biostór Ireland
  • BioTools
  • Boca Biolistics
  • Brooks Life Sciences
  • UNC BioSpecimen Processing Facility
  • Capital Biosciences
  • CellCarta (formerly Caprion-HistoGeneX)
  • Clinical Biosamples & Research Services
  • Clinical Logistics 
  • Clinical Trials Laboratory Services (CTLS)
  • Clinical OMICs
  • CliniSciences
  • Conversant Bio
  • Creative Bioarray
  • Cryoport
  • Cureline
  • Custom Science
  • Definiens
  • Delaware Health Information Network
  • Discovery Life Sciences
  • Doctors Pathology Services
  • Dx Biosamples
  • East West Biopharma
  • Eastern Biologix
  • Fidelis Research
  • Flagship Biosciences
  • Folio Biosciences
  • Fox Chase Cancer Center
  • Geneticist
  • Genohm (acquired by Agilent)
  • GLAS (acquired by Precision for Medicine)
  • Global BioClinical (GBC)
  • Gnosis 
  • GR BioResearch
  • Great Lakes Health Connect (GLHC)
  • Helomics 
  • HemaCare
  • HistoGeneX
  • Hoth Therapeutics
  • Infinity BiologiX
  • ICON
  • Indivumed
  • International Society for Biological and Environmental Repositories (ISBER)
  • Institute of Molecular and Cell Biology (IMCB)
  • iProcess
  • iSpecimen
  • KAC
  • KamTek
  • Keystone Biologicals (acquired by BioIVT)
  • Los Rios Community Colleges District
  • Maricopa Integrated Health System (MIHS)
  • Marshall Medical Centre
  • Mayo Clinic
  • Medicover
  • MolecularMD
  • MT Group
  • myOnsite HealthCare
  • National BioService (NBS)
  • NeuCyte
  • Nexelis
  • Obio
  • Oxford BioDynamics (OBD)
  • Personalis
  • Phylogeny
  • PPA Research Group
  • Precision for Medicine (formerly Epiontis)
  • PrecisionMed
  • Precision Medicine Group
  • PrimeBioNet
  • ProMedDx (acquired by Precision for Medicine)
  • Promega
  • ProteoGenex
  • Q&T Research
  • QualTek Molecular Laboratories (acquired by Discovery Life Sciences)
  • REPROCELL
  • Reveal Biosciences
  • Samples Force
  • SampleSmart
  • Sanguine BioSciences
  • Sapien Biosciences
  • Science Exchange
  • Shanghai Outdo Biotech
  • Shanghai Zhangjiang Biobank
  • Sofia Bio (acquired by Discovery Life Sciences)
  • Sofia Tech Park
  • StemExpress
  • The Salk Institute
  • Trans-Hit Biomarkers (acquired by Brooks Life Sciences)
  • TriCore Reference Laboratories
  • TriMetis
  • TriStar Technology
  • UHN Biospecimen Services
  • Ultivue
  • US Biolab
  • Us4Cure
  • Viroclinics-DDL
  • VitroVivo Biotech
  • West-Atlantic Partners
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...